MedPharm (formerly Tergus Pharma)

For all of you who followed Tergus on LinkedIn, as part of our merger with MedPharm we will be transitioning all of our LinkedIn activity to the official MedPharm Ltd page: https://lnkd.in/gDhtDchW If you haven't already, please be sure click on the link and follow us there!

Tergus is excited to announce that we are joining forces with MedPharm Ltd to establish the best-in-class end-to-end topical and transepithelial CDMO. Michael Kane has been appointed CEO of the merged company, which will operate under the MedPharm name. Michael previously served as the CEO of Tergus. The combined business will continue offering full commercial production capabilities, including high-potency and hormone-based drugs, and comprehensive serialization services. This merger adds enhanced automation, innovation, and expertise to our in vitro testing services, in addition to cutting-edge research models for drug development. Furthermore, with an expanded presence in the U.S. and facilities and MHRA/EMA experts in the U.K., our combined organization will be able to serve our clients with a global regulatory focus. The merger uniquely positions MedPharm as the premier CDMO focused on topical and transepithelial drug products. Click here to learn more: https://hubs.la/Q02FB52G0

Here in Philly with my colleague Tim Miley, ready to talk about Tergus' CDMO services!

We’re open for business at CPHI North America in Philadelphia! Come by booth 642 to talk about how Tergus can support your topical drug development and commercial production. #TeamTergus #TergusCDMO #CPHINorthAmerica

CPhI North America 2024 is here! Don’t miss a great opportunity to discuss your topical product with the topical experts at Booth #642! #CPhINorthAmerica #TopicalCDMO #TopicalDrugDevelopment #TopicalManufacturing

Did you know that Tergus has a purpose-built, cGMP, full-commercial production facility for topical products, including batch sizes from 30L to 1500L, separate dedicated HPAPI and hormone suites, and packaging capabilities for full turnkey CMO services? Let’s talk about it at CPhI North America next week, Booth #642. #CPhINorthAmerica #TopicalCDMO #TopicalDrugDevelopment #TopicalProduction

CPhI North America is a week away, so let’s schedule a meeting at our Booth #642 to discover how Tergus can put our unrivaled expertise in early- & late-stage R&D and full-scale commercial production to work for your topical product program. #CPhINorthAmerica #TopicalCDMO #TopicalDrugDevelopment #TopicalManufacturing

Did you know that April is Rosacea Awareness Month? Rosacea is a common skin condition effecting 415+ million people around the world. Rosacea causes flushing or long-term redness on the face. Symptoms can come and go, with flare-ups lasting for weeks or months. While there is no cure, symptoms can be controlled with medical therapy. As a leader in the development and manufacture of topical treatments, Tergus is committed to helping our clients find new products to treat this disease. https://hubs.la/Q02qYPyY0 #Rosacea #RosaceaAwarenessMonth #topicalformulations #topicalmanufacturing

DCAT Week 2024 is here! Don’t miss a great opportunity to discuss your topical product with the topical experts! https://hubs.la/Q02jpfVV0 #DCATWeek2024 #TopicalCDMO #TopicalDrugDevelopment #TopicalProduction

We’re rolling out the red carpet for our meeting guests at the Lotte New York Palace during DCAT Week next week. If you have a topical drug product in your portfolio, we should talk. https://hubs.la/Q02jpfWF0 #DCATWeek2024 #TopicalCDMO #TopicalDrugDevelopment #TopicalProduction